Progesterone Cream for Weight Loss? Honest Answer: Zero RCTs (Evidence Review)

The honest answer: there is no FDA-approved progesterone cream for weight loss, no high-quality RCT showing weight loss from topical progesterone, and topical OTC absorption is unreliable per FDA, ACOG, and The Menopause Society. Menopause weight gain is real, but it is driven by accelerated sarcopenia, reduced non-exercise activity, sleep disruption, and visceral fat redistribution — not by a progesterone deficit a cream can fix. Application site is the wrong question; the right question is what the evidence shows works.

At a glance

• Zero FDA-approved progesterone creams for weight loss. The FDA explicitly states that “ bioidentical hormones” sold by compounding pharmacies “are not FDA-approved” and that FDA “does not have evidence that compounded ‘bioidentical hormones’ are safe and effective”^[8].
• No high-quality RCT supports weight loss. The Whelan 2013 systematic review^[1] on compounded progesterone cream and the Benster 2009 placebo-controlled RCT^[2] found no significant benefit on vasomotor symptoms, mood, or libido vs placebo — and weight loss was not an endpoint that survived scrutiny.
• Topical absorption is variable and unreliable. The Menopause Society notes that compounded creams “ are not tested for safety and effectiveness or to prove that the active ingredients are absorbed appropriately”^[10]. Serum progesterone after OTC cream use is typically low and inconsistent across users.
• Menopause weight gain is real but mis-attributed. The Greendale 2019 SWAN longitudinal cohort^[3] documented a clear pattern: lean mass declines and fat mass (especially visceral) rises across the menopause transition. Shieh 2023 SWAN^[4] confirmed the body-composition shift. The driver is sarcopenia plus reduced activity, not an “estrogen dominance” that progesterone counteracts.
• What actually works for midlife weight management: resistance training, adequate protein (the Kuo 2022 whey meta-analysis in postmenopausal women^[5] supports ~1.2–1.6 g/kg/day with whey or food protein), sleep consolidation, and — when clinically indicated — GLP-1 receptor agonists.
• Magnitude vs GLP-1s: STEP-1 semaglutide^[6] −14.9% body weight at 68 weeks; SURMOUNT-1 tirzepatide^[7] −20.9% at 72 weeks. No progesterone cream RCT approaches even a fraction of that magnitude.
• Talk to a clinician. A NAMS-certified Menopause Practitioner (search via the menopause.org directory^[10]) can evaluate symptoms and discuss FDA-approved options if hormone therapy is appropriate. OTC topical creams are not a clinical substitute.

What progesterone does (and does not do) physiologically

Progesterone is a steroid hormone produced primarily by the corpus luteum after ovulation and by the placenta during pregnancy. Its established physiological roles are: preparing the endometrium for implantation, maintaining early pregnancy, modulating GABA-A neurotransmission (which is the mechanism behind progesterone’s sedating, mood-modulating effects when administered orally), and partially opposing estrogen at the endometrium to prevent endometrial hyperplasia in women receiving systemic estrogen.

What progesterone is not established to do: directly cause fat loss, increase basal metabolic rate, redirect fat from one body region to another, or reverse the body-composition changes that occur during the menopause transition. The peer-reviewed evidence supporting topical progesterone for weight loss is essentially absent. The Whelan 2013 Ann Pharmacother systematic review^[1] of bioidentical progesterone cream for menopause-related vasomotor symptoms identified only a handful of small RCTs, with body-composition endpoints either unreported or null. The Benster 2009 Menopause Int double-blind placebo-controlled trial^[2] of Progestelle progesterone cream in postmenopausal women found no statistically significant benefit on any primary endpoint.

OTC progesterone cream vs FDA-approved progesterone formulations

It is essential to distinguish between three different product categories, because they are not interchangeable and only one has rigorous FDA review behind it.

• FDA-approved oral micronized progesterone (Prometrium / generic). Indicated for the prevention of endometrial hyperplasia in postmenopausal women receiving systemic estrogen, and for secondary amenorrhea. Standard dose is 200 mg at bedtime (cyclical) or 100 mg daily (continuous combined regimen). Bioavailability and serum progesterone are characterized in the approval data. Weight loss is not an FDA-approved indication.
• FDA-approved vaginal progesterone gel (Crinone 8%). Indicated for progesterone supplementation / replacement as part of assisted reproductive technology and for secondary amenorrhea. Vaginal delivery achieves uterine tissue concentrations sufficient for endometrial support. Weight loss is not an FDA-approved indication.
• Compounded / OTC topical progesterone creams (ProgestaCare, Source Naturals, NaturalProgesterone, etc.). Not FDA-approved. The FDA states explicitly that compounded “bioidentical hormones” “are compounded drugs, which are not FDA-approved” and that “FDA does not have evidence that compounded ‘bioidentical hormones’ are safe and effective”^[8]. ACOG’s position is consistent — compounded bioidentical menopausal hormone therapy lacks the safety and efficacy data that supports FDA-approved hormone therapy products^[9].

The marketing framing “bioidentical” is doing a lot of work here. The Menopause Society points out that “bioidentical hormones do not have to be custom compounded” — there are many FDA-approved hormone therapy products (oral micronized progesterone, transdermal estradiol patches, vaginal estradiol) that meet the “bioidentical” chemical definition and are rigorously tested^[10]. The compounded OTC creams sold on Amazon, in health-food stores, and through telehealth compounding pharmacies are a different category — not FDA-reviewed, not standardized, and not supported by peer-reviewed weight-loss evidence.

What FDA, ACOG, and The Menopause Society actually say

On the question of compounded OTC progesterone creams, the three major regulatory and professional bodies are unusually aligned.

FDA, verbatim: “‘Bioidentical hormones’ are compounded drugs, which are not FDA-approved. FDA does not have evidence that compounded ‘bioidentical hormones’ are safe and effective”^[8]. The agency’s consumer-facing menopause page consistently directs users to FDA-approved hormone therapy products when clinically indicated, rather than to compounded OTC creams.

ACOG: The American College of Obstetricians and Gynecologists committee opinion on compounded bioidentical menopausal hormone therapy^[9] emphasizes that compounded BHT lacks the safety and efficacy data required of FDA-approved hormone therapy products, that there is no evidence compounded preparations are safer than FDA-approved alternatives, and that “hormone testing” (salivary or serum) to titrate compounded hormones is not supported by evidence.

The Menopause Society (formerly NAMS), verbatim: “Compounded hormones are not safer or more effective than approved bioidentical hormones. They are not tested for safety and effectiveness or to prove that the active ingredients are absorbed appropriately”^[10]. The Society’s NAMS-Certified Menopause Practitioner (NCMP) credential program trains clinicians in evidence-based menopause care and is the recommended pathway to find a qualified menopause clinician.

None of these three bodies endorse progesterone cream for weight loss as an indication. The convergent regulatory consensus is that compounded OTC bioidentical creams are not a tested, standardized intervention, and that any clinical decision about menopausal hormone therapy should go through a clinician familiar with FDA-approved options.

Topical absorption is unreliable: the serum-level evidence

Even setting aside the absence of weight-loss efficacy evidence, the more fundamental problem with OTC topical progesterone creams is that absorption is variable across users and typically delivers low serum progesterone concentrations. The Whelan 2013 systematic review^[1] summarized the literature: serum progesterone after topical application of OTC creams is typically in the low-ng/mL range or below, with substantial inter-individual variability. Application site (wrist, inner thigh, abdomen) has been studied in small pharmacokinetic samples, but no application site has been shown to produce clinically meaningful systemic progesterone or endometrial protection.

That last point is clinically load-bearing: oral micronized progesterone (Prometrium) is the FDA-approved standard precisely because it achieves reproducible serum levels that provide endometrial protection in women taking systemic estrogen. Compounded OTC creams have not been shown to achieve equivalent endometrial protection. The Menopause Society and ACOG both warn against using compounded progesterone creams as endometrial protection for women on unopposed systemic estrogen^[9][10].

The Benster 2009 Menopause Int placebo-controlled RCT of Progestelle progesterone cream^[2] measured both clinical outcomes and serum progesterone after twice-daily topical application in postmenopausal women. No significant effect on vasomotor symptoms, mood, or libido was observed vs placebo. Serum progesterone increases were modest and not clinically actionable. If the cream cannot reliably modulate the primary indications it is marketed for (hot flashes, mood), it is not credibly going to mobilize visceral fat.

Why menopause weight gain actually happens

Menopause-related weight changes are real and well-documented in longitudinal cohort data — but the mechanism is not what OTC progesterone cream marketing claims. The Greendale 2019 JCI Insight analysis of the Study of Women’s Health Across the Nation (SWAN)^[3], the canonical US longitudinal cohort of midlife women, characterized the body-composition trajectory across the menopause transition: accelerated loss of lean mass, gain in fat mass, and redistribution toward visceral and central fat depots. Shieh 2023 SWAN^[4] extended these findings, showing that the menopause-related body-composition shift is associated with downstream bone mineral density loss and fracture risk.

The proximate drivers of midlife weight gain in women, in rough order of magnitude:

• Accelerated sarcopenia. Lean mass declines ~0.2–0.6% per year across the perimenopausal and early postmenopausal years, faster than the gradual age-related decline in premenopausal years per SWAN cohort data^[3]. Because lean mass drives resting metabolic rate, this alone reduces daily energy expenditure by ~30–80 kcal/day cumulatively.
• Reduced non-exercise activity thermogenesis (NEAT). Midlife reductions in spontaneous movement — fidgeting, standing, walking, postural shifts — account for a larger share of midlife weight gain than most patients realize. NEAT is highly variable but can swing daily energy expenditure by 100–500 kcal.
• Sleep disruption. Vasomotor symptoms (hot flashes, night sweats), insomnia, and sleep-disordered breathing increase across the menopause transition. Reduced and fragmented sleep is independently associated with weight gain, increased visceral adiposity, and reduced insulin sensitivity.
• Visceral fat redistribution. Independent of total body weight, the menopause transition shifts fat deposition from a subcutaneous gluteofemoral pattern toward a central / visceral pattern — the same metabolically adverse pattern seen in men. This is largely driven by the loss of ovarian estrogen, not by a progesterone deficit.
• Caloric intake stays roughly flat while expenditure drops. Most women do not reduce caloric intake to match the ~50–150 kcal/day decrement in expenditure across the menopause transition, producing a small positive energy balance that compounds across years.

None of these mechanisms is “estrogen dominance fixable with progesterone cream.” That framing — popularized by functional-medicine writers, not by peer-reviewed endocrinology — misattributes the midlife body-composition shift to a hormonal imbalance that a topical cream can correct. The actual driver mix is largely addressable, but the levers are different.

What actually works for menopause-era weight management

The honest answer is that the interventions with the best evidence for midlife weight management are not hormone creams. They are behavioral and (when clinically indicated) pharmacological.

• Resistance training, 2–3 sessions per week. Resistance training is the single most effective behavioral lever for the dominant midlife mechanism (accelerated sarcopenia). It preserves and partially rebuilds lean mass, supports resting metabolic rate, and improves insulin sensitivity. Multi-joint compound movements (squat, hinge, push, pull) at moderate loads with progressive overload deliver the best signal in postmenopausal RCTs.
• Adequate protein intake (~1.2–1.6 g/kg/day, higher if active). The Kuo 2022 Nutrients meta-analysis of whey protein supplementation in postmenopausal women^[5] documented improvements in lean mass and body composition outcomes with whey protein added to resistance training. Food-source protein works similarly; the per-meal anchor (~25–30 g protein at breakfast and lunch) is the practical lever.
• Sleep consolidation. Treating vasomotor symptoms (with FDA-approved menopausal hormone therapy if clinically appropriate, or non-hormonal alternatives like fezolinetant), addressing sleep-disordered breathing if present, and basic sleep hygiene compound into measurable weight and metabolic benefit.
• Cardiovascular activity. 150–300 min/week of moderate-intensity activity supports cardiometabolic health and modest energy-balance gains; higher volumes deliver larger weight-loss signals but the marginal return diminishes.
• GLP-1 receptor agonist therapy when clinically indicated. For women with obesity (BMI ≥30) or overweight (BMI 27–29.9) with weight-related comorbidities, FDA-approved GLP-1 receptor agonist therapy (semaglutide / Wegovy, tirzepatide / Zepbound) delivers the largest weight-loss signals in published clinical trials. STEP-1^[6] showed −14.9% body weight at 68 weeks on semaglutide 2.4 mg; SURMOUNT-1^[7] showed −20.9% body weight at 72 weeks on tirzepatide 15 mg. See our HRT, perimenopause and GLP-1 evidence review for the menopause-specific framing.
• FDA-approved menopausal hormone therapy when clinically indicated. For women with significant vasomotor symptoms, FDA-approved hormone therapy (transdermal estradiol ± oral micronized progesterone, depending on uterine status) is the guideline-supported treatment per The Menopause Society and ACOG. The indication is symptom relief and bone protection — not weight loss. See GLP-1, HRT, and menopausal weight evidence for the combined-therapy evidence.

Importantly, the interventions on this list compound. A resistance-trained, protein-adequate, well-rested midlife woman on FDA-approved hormone therapy (if symptom-indicated) and GLP-1 receptor agonist therapy (if obesity-indicated) has access to the most evidence-supported weight-management toolkit available. None of those tools is an OTC topical cream.

Where the “progesterone cream for weight loss” idea actually comes from

The marketing premise behind OTC progesterone creams traces primarily to popular-press functional-medicine writing from the 1990s and 2000s — specifically the “estrogen dominance” framework, which posits that midlife women have too much estrogen relative to progesterone and that topical progesterone restores balance. This framing was never based on peer-reviewed endocrinology. The actual hormonal trajectory of the menopause transition is the opposite: estrogen levels decline (substantially, eventually) while progesterone declines too (because cycles become anovulatory before estrogen drops fully). The “dominance” framing inverts the physiology.

We are not going to direct readers to the source authors of the “estrogen dominance” framing — the peer-reviewed evidence base does not support it, and citing functional-medicine blogs as authorities would undermine the article’s evidentiary standard. The reasonable next question for a reader who has been told “take progesterone cream” is: who told you that, and what evidence are they pointing to? If the answer is a wellness Instagram account, an MLM rep, or a compounding pharmacy sales page — not a NAMS-certified menopause clinician — the recommendation is operating outside the evidence base.

What to ask a clinician (NAMS-certified Menopause Practitioner)

If midlife weight changes, vasomotor symptoms, sleep disruption, or mood changes are the underlying concern, the evidence-based pathway is a clinician evaluation, not an OTC cream purchase. The Menopause Society maintains a NAMS-Certified Menopause Practitioner (NCMP) directory at menopause.org^[10] that lists clinicians trained specifically in evidence-based menopause care.

Useful questions for that visit:

• What is the most likely driver of my weight changes given my menopause stage, sleep, activity level, and protein intake? Where would symptom-targeted treatment have the most impact?
• Am I a candidate for FDA-approved menopausal hormone therapy based on symptom burden, age, time since menopause, and cardiovascular / breast-cancer risk profile? If yes, what is the appropriate route and formulation?
• Do I meet criteria (BMI, comorbidity profile) for FDA-approved obesity pharmacotherapy, and how would it interact with menopausal hormone therapy if I am on it? See our HRT + GLP-1 evidence review for the combined-therapy literature.
• Are vasomotor symptoms or sleep apnea contributing to fragmented sleep, and is symptom-targeted treatment appropriate?
• Can you connect me with a registered dietitian or trainer who works with midlife women for the resistance-training-and-protein-adequacy lever?

The questions a NAMS-certified clinician is not likely to recommend: “Should I apply compounded progesterone cream to my wrists, inner thighs, or abdomen for weight loss?” The honest clinical answer is that the application site does not change the underlying problem: topical OTC progesterone is not a tested weight-loss intervention, and the time and money spent on it is better directed at interventions with actual evidence.

Red flags in compounded BHRT marketing

Compounded bioidentical hormone replacement therapy (BHRT) marketing — including OTC progesterone creams sold through online compounding pharmacies and wellness telehealth clinics — relies on a consistent set of claims that ACOG and The Menopause Society have explicitly flagged as unsupported by evidence.

• “Hormone testing to customize your dose.” Salivary hormone testing to titrate compounded BHT is not supported by ACOG or The Menopause Society. Salivary hormone concentrations correlate poorly with clinically relevant systemic exposure and do not guide dosing of FDA-approved hormone therapy.
• “Safer than synthetic hormones.” Compounded BHT is not safer than FDA-approved hormone therapy. The active molecules in FDA-approved oral micronized progesterone and transdermal estradiol are chemically identical to endogenous human hormones — the regulatory difference is that FDA-approved products are tested for purity, potency, and consistent absorption, while compounded preparations are not.
• “Approved by the FDA.” Compounded preparations are not FDA-approved as drug products. Some compounding facilities are FDA-registered as 503A or 503B compounding pharmacies, but the preparations themselves are not approved drug products and have not been through FDA efficacy and safety review.
• “Estrogen dominance is causing your weight gain.” The estrogen-dominance framework is not supported by peer-reviewed endocrinology of the menopause transition. Estrogen and progesterone both decline; the ratio framing does not map onto the actual physiology.
• “Personalized hormone cream for weight loss and hot flashes.” No compounded progesterone cream has demonstrated weight loss in a well-conducted RCT, and the evidence on vasomotor symptom relief from compounded creams is also weak^[1][2]. The marketing extrapolates beyond what the evidence supports.
• “Endometrial protection from compounded progesterone cream.” ACOG and The Menopause Society explicitly warn against this use^[9][10]. Women on systemic estrogen who require endometrial protection need FDA-approved oral micronized progesterone, an IUD with progestin, or another guideline-supported option.

Encountering several of these claims in a single product page or telehealth consult is a reasonable signal to seek a NAMS-certified second opinion before proceeding.

Bottom line

• There is no FDA-approved progesterone cream for weight loss. There is no high-quality RCT showing weight loss from topical OTC progesterone. The compounded OTC creams sold for menopausal weight management are not FDA-approved per the FDA^[8], ACOG^[9], and The Menopause Society^[10].
• Topical absorption from OTC creams is variable and typically produces low, inconsistent serum progesterone concentrations. The Whelan 2013 systematic review^[1] and Benster 2009 RCT^[2] are consistent with this conclusion.
• Menopause weight gain is real but is driven by accelerated sarcopenia, reduced NEAT, sleep disruption, and visceral fat redistribution — not by a progesterone deficit a topical cream can correct. Greendale 2019 SWAN^[3] and Shieh 2023 SWAN^[4] document the body-composition trajectory.
• What does work: resistance training, ~1.2–1.6 g/kg/day protein (the Kuo 2022 whey meta-analysis^[5] supports the protein-anchored midlife intervention), sleep consolidation, and — when clinically indicated — FDA-approved obesity pharmacotherapy and FDA- approved menopausal hormone therapy.
• Magnitude vs GLP-1s: STEP-1 semaglutide^[6] −14.9% body weight at 68 weeks; SURMOUNT-1 tirzepatide^[7] −20.9% at 72 weeks. The gap between “no signal in topical progesterone cream RCTs” and “15–21% body weight on FDA-approved GLP-1 therapy” is two orders of magnitude.
• The pragmatic recommendation: consult a NAMS-certified Menopause Practitioner. The “where-do-I-apply-the-cream” question has no evidence-based answer because the cream itself does not have evidence-based weight-loss efficacy. Direct your time, money, and attention at the levers that do.

Related research and tools

• HRT, perimenopause, and GLP-1 in midlife women — the combined-therapy evidence review covering where FDA-approved hormone therapy and GLP-1 therapy intersect for midlife women.
• GLP-1, HRT, and menopausal weight evidence — the parallel evidence review on estrogen and weight changes during the menopause transition.
• GLP-1 and the menstrual cycle / period / hormones — how GLP-1 receptor agonists interact with ovarian-cycle physiology in premenopausal women.
• OTC GLP-1 supplements: evidence review — the parallel framework for evaluating non-prescription supplements marketed for weight loss. Same evidentiary standard applied to a different category.
• Mounjaro / Zepbound and birth control: the FDA warning — the FDA contraceptive-efficacy interaction warning for tirzepatide, relevant for premenopausal women considering GLP-1 therapy.
• Birth control and weight loss: evidence review — the parallel evidence review on hormonal contraception and body weight.
• Supplement evidence grader tool — an interactive tool that grades supplement weight-loss claims by RCT count, evidence quality, and magnitude. Useful frame for evaluating any OTC product marketed for weight loss.
• Wegovy / Ozempic (semaglutide) — STEP-1 magnitude reference (−14.9% body weight at 68 weeks).
• Zepbound / Mounjaro (tirzepatide) — SURMOUNT-1 magnitude reference (−20.9% body weight at 72 weeks).

Important disclaimer. This article is educational and does not constitute medical advice. It is not a recommendation to take or to avoid progesterone in any form. Women considering hormone therapy — FDA-approved or otherwise — should consult a NAMS-certified Menopause Practitioner or other qualified clinician. Women currently using compounded OTC progesterone cream as endometrial protection while taking systemic estrogen are specifically advised to discuss this with their clinician, because ACOG and The Menopause Society both flag this as inadequate endometrial protection^[9][10]. Women with breast cancer, endometrial cancer, unexplained vaginal bleeding, or thromboembolic history should not initiate any hormone therapy without clinician guidance. GLP-1 receptor agonist therapy and menopausal hormone therapy are prescription decisions made between a patient and a qualified clinician; nothing in this article should be interpreted as a personalized treatment recommendation. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-25; external regulatory URLs were verified live on the same date.

Last verified: 2026-05-25. Next review: every 12 months, or sooner if major new evidence on progesterone cream, menopausal hormone therapy, or midlife-women weight-management pharmacotherapy is published.